Ran this past a path friend, here was his comment fwiw:
From my quick look, I think they are going to have to do a lot better than this to have something that is of any use. Most dermpaths think by morphology alone they only need help with a very small percentage of cases. It looks like these FISH probes pick up aneuploidy in a way that corresponds with morphologic atypia, and is positive in benign nevi with atypia to the tune of 10% if memory serves. This is just telling the pathologist what they already know, that the lesion is atypical. If I have a difficult case and you tell me the test misses ~20% of easily diagnosed malignancies (how does it do with tough ones? they threw those out), I have little faith in a negative result. Not that helpful.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.